News_News_Qijian Bio-Pharmaceutical Co.,Ltd.

Home
About us 
Profiles Development Culture Honor Enterprise Style
Product 
Pharmaceutical products Medical Products
News 
Qijian News Industry news Social News Staff style Corporate Video
CDMO
Contact 
Feedback Contact Attract talents

新闻资讯





Homepage

News

THE 3RD WORLD CONFERENCE ON SCIENCE AND TECHNOLOGY OF TCM AND THE 2024 CHANGCHUNINTERNATIONAL MEDICINE& HEALTH INDUSTRY EXPO

06 2024/12

Good news | Jilin Qijian Bio-Pharmaceutical Co., Ltd. passed the pharmaceutical GMP compliance inspection

Our company's butylphthalide API production line has successfully passed the pharmaceutical GMP compliance inspection of the National Medical Products Administration. This successful passing of the GMP compliance inspection is not only a recognition of Qijian's existing production capacity and quality management level, but also opens up a broader space for for the future development of the company.

27 2024/11

Good news | Jilin Qijian Bio-Pharmaceutical Co., Ltd. passed the pharmaceutical GMP compliance inspection

Good News! Qijian’s butylphthalide API was granted a registration number

Jilin Qijian’s butylphthalide API was successfully approved for market listing on 12th Nov 2024. this marks a significant progress of our drug research and development. This achievement not only lays a solid foundation for the clinical application of butylphthalide injection, but also opens up a broad prospect for our company in R&D and production in the future. The successful application for the registration number of butylphthalide API is the result of our company's long-term investment and unremitting efforts in the field of drug research and development. On the basis of in-depth research on the pharmacological mechanism of butylphthalide, our R&D team has continuously optimized the production process and quality control standards to ensure the safety and efficacy of the product. At the same time, we also actively communicated and collaborated with China FDA and other relevant departments, declared in strict accordance with the relevant regulations and guidelines, and ultimately obtained this important achievement. In the future, we will continue to increase investment in research and development, deepen cooperation with domestic and foreign research institutions and medical institutions, and promote the research and development and application of innovative medicines, so as to bring benefits to more patients. We will continue to uphold the corporate spirit of ‘Integrity, Innovation and Responsibility’ and commit ourselves to provide patients around the world with safer, more effective and more convenient medicines and services. At the same time, we will also actively fulfil our social responsibility and promote the healthy and sustainable development of the pharmaceutical industry.

14 2024/11

Good News! Qijian’s butylphthalide API was granted a registration number

"Human growth hormone (HGH) injection" received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)!

On October 10, 2024, the product "Human growth hormone (HGH) injection" developed by Jilin Qijian Bio-pharmaceutical Co., Ltd. received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA) The development of human growth hormone (HGH) injection is the crystallization of the unremitting efforts and innovative spirit of the R&D team, it not only demonstrate the company's profound foundation and forward-looking vision in the field of bio-pharmaceuticals, but also injected a strong impetus to the overall jump in the company's R&D strength.It marks a breakthrough progress in the company’s research and development of new products in the endocrine field, which will help further optimize the company's product structure, enrich it’s product pipeline, enhance the company's overall R&D capabilities, and enhance the company's long-term profitability.

25 2024/10

"Human growth hormone (HGH) injection" received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)!

The 2024 CPhI Milan in October is ongoing now

10 2024/10

The 12th MEXICO-CHINA INVEST & TRADE EXPO

The 12th MEXICO-CHINA INVEST & TRADE EXPO. Qijianbio China achieved a complete success!

01 2024/08

…

Feedback

Mobile

0086-431-81285900

WeChat

TOP

Username used for comment:

客户留言

Description:

* Message content：

Name：

Mobile：

Add：

WeChat

ADD： No.707 Chaofan street, High-Tech Industrial Development Zone, Changchun City, Jilin province, China
Service Hotline：0086-431-81285900
Fax：0086-431-88794098
Email：export@qijianbio.com

Member Login | Mailbox

搜索